Competitive ELISA for the Detection of Serum Antibodies Specific for Middle East Respiratory Syndrome Coronavirus (MERS-CoV).
Methods Mol Biol
; 2203: 55-65, 2020.
Article
in English
| MEDLINE | ID: covidwho-761346
ABSTRACT
Middle East respiratory syndrome coronavirus (MERS-CoV) is the etiological agent of MERS, a severe respiratory disease first reported in the Middle East in 2012. Serological assays are used to diagnose MERS-CoV infection and to screen for serum antibodies in seroepidemiological studies. The conventional enzyme-linked immunosorbent assay (ELISA) is the preferred tool for detecting serum antibodies specific for pathogens; however, the utility of conventional ELISA with respect to detection of MERS-CoV antibodies is limited due to the number of false-positives caused by cross-reactivity of serum antibodies with antigens that are conserved among coronaviruses. The competitive ELISA (cELISA) uses a pathogen-specific monoclonal antibody (MAb) that competes with serum antibodies for binding to an antigen; therefore, it is used widely for serological surveillance of many pathogens. In this chapter, I describe detection of serum antibodies using cELISA based on MAbs specific for MERS-CoV.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Enzyme-Linked Immunosorbent Assay
/
Coronavirus Infections
/
Middle East Respiratory Syndrome Coronavirus
/
Antibodies, Viral
Type of study:
Diagnostic study
/
Etiology study
/
Observational study
/
Randomized controlled trials
Limits:
Animals
/
Humans
Language:
English
Journal:
Methods Mol Biol
Journal subject:
Molecular Biology
Year:
2020
Document Type:
Article
Affiliation country:
978-1-0716-0900-2_4
Similar
MEDLINE
...
LILACS
LIS